A 78 kDa
gastrin-
binding protein (GBP) has previously been identified as the target of the anti-proliferative effects of non-selective
gastrin/
cholecystokinin receptor antagonists on
colorectal carcinoma cell lines. The GBP was related in sequence to a family of
fatty acid oxidation
enzymes possessing
enoyl CoA hydratase and 3-hydroxyacyl
CoA dehydrogenase activity. This study aims to define the binding site for
gastrin and
gastrin antagonists in greater detail. The N- and C-terminal halves of the porcine GBP were expressed independently as
glutathione S-transferase fusion
proteins in E. coli. Affinities of
gastrin and
gastrin antagonists for the fusion
proteins were measured by competition for 125I-[Nle15]-
gastrin binding in a covalent cross-linking assay. The N- and C-terminal fusion
proteins bound
gastrin with affinities of 9.9 +/- 6.1 and 71 +/- 48 microM, respectively (n = 3). These values were 40-fold and 300-fold lower than the affinity of the full-length GBP for
gastrin (0.23 +/- 0.15 microM). In contrast, the affinities of the N- and C-terminal halves for the antagonists
proglumide (22 +/- 13 and 10 +/- 4 mM, respectively) and
benzotript (350 +/- 90 and 400 +/- 160 micro M, respectively) were similar to each other and to the affinities of
proglumide and
benzotript for the full-length GBP (5.1 +/- 3.6 mM and 200 +/- 120 microM, respectively). It is concluded that
proglumide and
benzotript bind independently to both the hydratase and
dehydrogenase active sites of the GBP, while a single molecule of
gastrin may bind simultaneously to both active sites. A model is proposed which is consistent with these data, and which will assist in the development of more potent and selective GBP antagonists.